An optogenetic arrhythmia model to study catecholaminergic polymorphic ventricular tachycardia mutations

被引:11
|
作者
Fischer, Elisabeth [1 ,2 ,4 ]
Gottschalk, Alexander [1 ,2 ,3 ]
Schueler, Christina [1 ,2 ]
机构
[1] Goethe Univ, Buchmann Inst Mol Life Sci, Max von Laue Str 15, D-60438 Frankfurt, Germany
[2] Goethe Univ, Inst Biophys Chem, Max von Laue Str 15, D-60438 Frankfurt, Germany
[3] Goethe Univ, Cluster Excellence Frankfurt Macromol Complexes, Max von Laue Str 15, D-60438 Frankfurt, Germany
[4] Univ Edinburgh, Ctr Integrat Physiol, Hugh Robson Bldg,George Sq, Edinburgh EH8 9XE, Midlothian, Scotland
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
关键词
RYANODINE RECEPTOR GENE; STEM-CELL MODEL; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; MOUSE MODEL; IN-VITRO; CALSEQUESTRIN; CHANNEL; ARRHYTHMOGENESIS;
D O I
10.1038/s41598-017-17819-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition of abnormal heart rhythm (arrhythmia), induced by physical activity or stress. Mutations in ryanodine receptor 2 (RyR2), a Ca2+ release channel located in the sarcoplasmic reticulum (SR), or calsequestrin 2 (CASQ2), a SR Ca2+ binding protein, are linked to CPVT. For specific drug development and to study distinct arrhythmias, simple models are required to implement and analyze such mutations. Here, we introduced CPVT inducing mutations into the pharynx of Caenorhabditis elegans, which we previously established as an optogenetically paced heart model. By electrophysiology and video-microscopy, we characterized mutations in csq-1 (CASQ2 homologue) and unc-68 (RyR2 homologue). csq-1 deletion impaired pharynx function and caused missed pumps during 3.7 Hz pacing. Deletion mutants of unc-68, and in particular the point mutant UNC-68(R4743C), analogous to the established human CPVT mutant RyR2(R4497C), were unable to follow 3.7 Hz pacing, with progressive defects during long stimulus trains. The pharynx either locked in pumping at half the pacing frequency or stopped pumping altogether, possibly due to UNC-68 leakiness and/or malfunctional SR Ca2+ homeostasis. Last, we could reverse this 'worm arrhythmia' by the benzothiazepine S107, establishing the nematode pharynx for studying specific CPVT mutations and for drug screening.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Knock-in mouse model of catecholaminergic polymorphic ventricular tachycardia
    Colombi, B.
    Cerrone, M.
    Santoro, M.
    di Barletta, M. Raffaele
    Napolitano, C.
    Priori, S. G.
    EUROPEAN HEART JOURNAL, 2005, 26 : 16 - 16
  • [32] The Relationship Between Ventilatory Anaerobic Threshold and Arrhythmia in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
    Aronoff, Elizabeth B.
    Baskar, Shankar
    Czosek, Richard J.
    Mays, Wayne A.
    Spar, David S.
    Knilans, Timothy K.
    Powell, Adam W.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2024, 10 (02) : 373 - 375
  • [33] ALTERNANS AND ARRHYTHMIA IN GENETICALLY MODIFIED MURINE HEARTS MODELLING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA
    Sabir, I. N.
    Ma, N.
    Jones, V. J.
    Goddard, C. A.
    Zhang, Y.
    Kalin, A.
    Grace, A. A.
    Christopher, L. H.
    HEART, 2009, 95 : A85 - A86
  • [34] Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia
    Cerrone, Marina
    Noujaim, Sami F.
    Tolkacheva, Elena G.
    Talkachou, Arkadzi
    O'Connell, Ryan
    Berenfeld, Omer
    Anumonwo, Justus
    Pandit, Sandeep V.
    Vikstrom, Karen
    Napolitano, Carlo
    Priori, Silvia G.
    Jalife, Jose
    CIRCULATION RESEARCH, 2007, 101 (10) : 1039 - 1048
  • [35] Prevention of fatal arrhythmia in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation
    Wakinnoto, Hiroko
    Alcalai, Ronny
    Song, Lei
    Arad, Michael
    Seidman, Christine E.
    Seidman, Jonathan G.
    Berul, Charles I.
    CIRCULATION, 2007, 116 (16) : 216 - 216
  • [36] Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy
    Kohli, Utkarsh
    Aziz, Zaid
    Beaser, Andrew D.
    Nayak, Hemal M.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2020, 43 (05): : 527 - 533
  • [37] Mechanisms of abnormal calcium homeostasis in mutations responsible for catecholaminergic polymorphic ventricular tachycardia
    Iyer, Vivek
    Hajjar, Roger J.
    Armoundas, Antonis A.
    CIRCULATION RESEARCH, 2007, 100 (02) : E22 - E31
  • [38] A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations
    De la Fuente, Sam
    Van Langen, Irene M.
    Postma, Alex V.
    Bikker, Henni
    Meijer, Albert
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2008, 31 (07): : 916 - 919
  • [39] Simultaneous Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome Gene Mutations
    Lakhana, Muhddesa
    McGee, James
    George, Blessen
    Whang, William
    Kanner, Lawrence
    Park, Won Jun
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [40] Prevention of Ventricular Arrhythmia and Calcium Dysregulation in a Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model Carrying Calsequestrin-2 Mutation
    Alcalai, Ronny
    Wakimoto, Hiroko
    Arad, Michael
    Planer, David
    Konno, Tetsuo
    Wang, Libin
    Seidman, Jon G.
    Seidman, Christine E.
    Berul, Charles I.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2011, 22 (03) : 316 - 324